Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LOXL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LOXL2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View LOXL2 Products |
| Gene Delivery | LOXL2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer, sequence verified. |
View LOXL2 Products |
| Benchmark Ab | Anti-LOXL2 (Sequence of Simtuzumab) Recombinant positive control antibody. Sequence verified, high purity. |
View LOXL2 Products |
| Validator | LOXL2 siRNA Set For knockdown verification in functional assays. |
View LOXL2 Products |
| Related Target A | LOX Lysyl oxidase. Critical counter-screening target to prevent cardiovascular toxicity. |
View LOX Products |
| Related Target B | LOXL1 Lysyl oxidase-like 1. Essential for elastic fiber homeostasis; crucial for selectivity screening. |
View LOXL1 Products |
| Related Target C | LOXL3 Lysyl oxidase-like 3. Highly homologous to LOXL2; required for specificity profiling. |
View LOXL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity Profiling | Human LOX, LOXL1, LOXL2, LOXL3, and LOXL4 ortholog proteins strictly verified by mass spectrometry and sequence analysis. |
| Species Cross-Reactivity | Human, Mouse, and Cynomolgus LOXL2 recombinant proteins available with >95% purity and controlled endotoxin levels. |
| Lack of Controls | Clinical Benchmark Antibodies (Simtuzumab biosimilar) included to validate binding and inhibition baselines. |
| False Positives in Knockdown | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live LOXL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LOXL2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to highly selective small molecule inhibitors and multi-target antifibrotic agents. As first-generation therapies like Simtuzumab reached the clinic and revealed the necessity of precise target engagement, the next wave of R&D is targeting specific enzymatic conformations and dual LOXL2/LOXL3 inhibition to maximize therapeutic efficacy in MASH (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective) | Pharmaxis, PharmAkeia, Pliant Therapeutics | MASH, Idiopathic Pulmonary Fibrosis (IPF), Myelofibrosis | Selectivity Assay (Need recombinant LOX, LOXL1, LOXL2, LOXL3, LOXL4 panel to avoid off-target lysyl oxidase inhibition) |
| Monoclonal Antibody | Gilead (Simtuzumab historical data) | Liver Fibrosis, Solid Tumors (Desmoplastic) | Epitope Mapping & Binding Kinetics (Need highly pure, native glycosylated HEK293-expressed LOXL2 ECD-Fc) |
| RNA Therapeutics | Alnylam, local biotech players | Hypertrophic Scars, Localized Fibrosis | In Vitro Knockdown Validation (Need sequence-verified siRNA and high-titer Lentivirus for stable reporter cell lines) |